US 12,251,492 B2
Nanofiber-reinforced hydrogel medical dressings
Lauren Anne Costella, Roanoke, VA (US); Christopher K. Tison, Roanoke, VA (US); Matthew Patterson, Roanoke, VA (US); Keley Broderick, Roanoke, VA (US); Lindsay Woodard, Roanoke, VA (US); and Mallory Gasbarre, Roanoke, VA (US)
Assigned to LUNA LABS USA, LLC, Charlottesville, VA (US)
Appl. No. 17/046,464
Filed by LUNA INNOVATIONS INCORPORATED, Roanoke, VA (US)
PCT Filed Apr. 8, 2019, PCT No. PCT/US2019/026254
§ 371(c)(1), (2) Date Oct. 9, 2020,
PCT Pub. No. WO2019/199630, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/654,651, filed on Apr. 9, 2018.
Prior Publication US 2021/0154356 A1, May 27, 2021
Int. Cl. A61L 26/00 (2006.01)
CPC A61L 26/008 (2013.01) [A61L 26/0014 (2013.01); A61L 26/0023 (2013.01); A61L 26/0028 (2013.01); A61L 26/0066 (2013.01); A61L 26/0071 (2013.01); A61L 26/0095 (2013.01); A61L 2300/406 (2013.01); A61L 2300/41 (2013.01); A61L 2300/64 (2013.01); A61L 2400/12 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A sutureless ocular medical dressing comprising:
a thiolated chitosan hydrogel matrix which comprises a deacetylated chitosan having a degree of deacetylation (DD) of between 40 to 100%, and
a non-woven polymeric nanofiber mat embedded in the thiolated chitosan hydrogel matrix, wherein
the thiolated chitosan hydrogel is thiolated with a thiolation agent selected from the group consisting of thioglycolic acids, glutathiones and cysteine compounds so as to be functionalized with a thiol group configured to form disulfide bonds with corneal tissue and thereby adhere the ocular medical dressing to the corneal tissue without sutures.